The BWH/Harvard Cohorts Biorespository is working with the Moderate Alcohol Use and Cardiovascular Health (MACH15) Trial.
MACH15 is a large-scale, international research trial funded by the National Institutes of Health to primarily determine the effects of moderate alcohol intake daily compared with abstention on risk of major cardiovascular events or death (myocardial infarction, ischemic stroke, hospitalized angina, need for revascularization, or death) over an average of 6 years of follow-up among adults with estimated 10-year CVD risk ≥15% or prevalent CVD >6 months prior to enrollment. The trial will enroll 7,800 participants ages 50 and older at more than 20 clinics worldwide. Enrollment will begin in Summer 2017.
The BWH/Harvard Cohorts Biorespository is serving as the central biorepository for the clinical trial.